BNT162b2疫苗诱导产生的血清对N501Y突变型严重急性呼吸综合征冠状病毒2的中和作用。
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
作者信息
Shi Pei-Yong, Xie Xuping, Zou Jing, Fontes-Garfias Camila, Xia Hongjie, Swanson Kena, Cutler Mark, Cooper David, Menachery Vineet, Weaver Scott, Dormitzer Philip
机构信息
The University of Texas Medical Branch at Galveston.
University of Texas Medical Branch.
出版信息
Res Sq. 2021 Jan 13:rs.3.rs-143532. doi: 10.21203/rs.3.rs-143532/v1.
Abstract
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic N501 and Y501 SARS-CoV-2. Twenty human sera from the mRNA-based vaccine BNT162b2 trial exhibited equivalent neutralizing titers to the N501 and Y501 viruses.
摘要
在英国和南非出现的快速传播的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体都有刺突蛋白N501Y替换，这尤其令人担忧，因为它位于病毒进入细胞的受体结合位点，会增加与受体的结合。我们构建了同基因的N501和Y501 SARS-CoV-2。来自基于信使核糖核酸的疫苗BNT162b2试验的20份人血清对N501和Y501病毒表现出同等的中和效价。
相似文献
1
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.BNT162b2疫苗诱导产生的血清对N501Y突变型严重急性呼吸综合征冠状病毒2的中和作用。
Res Sq. 2021 Jan 13:rs.3.rs-143532. doi: 10.21203/rs.3.rs-143532/v1.
2
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.BNT162b2疫苗诱导产生的血清对N501Y突变型严重急性呼吸综合征冠状病毒2的中和作用。
bioRxiv. 2021 Jan 7:2021.01.07.425740. doi: 10.1101/2021.01.07.425740.
3
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera.BNT162b2疫苗诱导产生的血清对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白69/70缺失、E484K和N501Y变体的中和作用
bioRxiv. 2021 Jan 27:2021.01.27.427998. doi: 10.1101/2021.01.27.427998.
4
Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.分析 BNT162b2- 和 CVnCoV 诱导的血清以及对 SARS-CoV-2 病毒的恢复期血清。
Allergy. 2022 Jul;77(7):2080-2089. doi: 10.1111/all.15189. Epub 2021 Dec 2.
5
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.BNT162b2 疫苗诱导的血清对 SARS-CoV-2 刺突 69/70 缺失、E484K 和 N501Y 变异株的中和作用。
Nat Med. 2021 Apr;27(4):620-621. doi: 10.1038/s41591-021-01270-4. Epub 2021 Feb 8.
6
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.康复期血清和BNT162b2 mRNA疫苗诱导的抗体对具有欧洲、南非和美国SARS-CoV-2变异株刺突蛋白的病毒的中和作用。
bioRxiv. 2021 Feb 7:2021.02.05.430003. doi: 10.1101/2021.02.05.430003.
7
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体对许多单克隆抗体和血清来源的多克隆抗体介导的中和作用表现出抗性。
Res Sq. 2021 Feb 10:rs.3.rs-228079. doi: 10.21203/rs.3.rs-228079/v1.
8
The basis of a more contagious 501Y.V1 variant of SARS-COV-2.新冠病毒更具传染性的501Y.V1变种的基础。
bioRxiv. 2021 Feb 2:2021.02.02.428884. doi: 10.1101/2021.02.02.428884.
9
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
10
Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.BNT162b2、mRNA-1273和Ad26.COV2.S诱导的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的IgG和中和抗体滴度的比较
Vaccines (Basel). 2022 May 27;10(6):858. doi: 10.3390/vaccines10060858.
引用本文的文献
1
SARS-CoV-2 B.1.1.7 UK Variant of Concern Lineage-Related Perceptions, COVID-19 Vaccine Acceptance and Travel Worry Among Healthcare Workers.SARS-CoV-2 B.1.1.7 关注变异株相关认知、医护人员对 COVID-19 疫苗的接受程度和旅行担忧
Front Public Health. 2021 May 26;9:686958. doi: 10.3389/fpubh.2021.686958. eCollection 2021.
2
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic.SARS-CoV-2 和 COVID-19 的病毒特性、传播、病理生理学、免疫反应和管理的全面综述，为控制大流行提供了依据。
Front Immunol. 2021 Feb 26;12:631139. doi: 10.3389/fimmu.2021.631139. eCollection 2021.
本文引用的文献
1
An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.一种针对 SARS-CoV-2 的工程化诱饵受体广泛结合蛋白 S 序列变体。
Sci Adv. 2021 Feb 17;7(8). doi: 10.1126/sciadv.abf1738. Print 2021 Feb.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
Spike mutation D614G alters SARS-CoV-2 fitness.刺突突变 D614G 改变了 SARS-CoV-2 的适应性。
Nature. 2021 Apr;592(7852):116-121. doi: 10.1038/s41586-020-2895-3. Epub 2020 Oct 26.
4
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
5
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.一种高通量中和抗体检测方法用于 COVID-19 的诊断和疫苗评估。
Nat Commun. 2020 Aug 13;11(1):4059. doi: 10.1038/s41467-020-17892-0.
6
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.用于测试疫苗效力的 SARS-CoV-2 在 BALB/c 小鼠中的适应性。
Science. 2020 Sep 25;369(6511):1603-1607. doi: 10.1126/science.abc4730. Epub 2020 Jul 30.
7
An Infectious cDNA Clone of SARS-CoV-2.严重急性呼吸综合征冠状病毒 2 的感染性 cDNA 克隆。
Cell Host Microbe. 2020 May 13;27(5):841-848.e3. doi: 10.1016/j.chom.2020.04.004. Epub 2020 Apr 13.
Zotero 插件